

## **EBMT LWP Open Research Forum 26<sup>th</sup> September 2018**

**Present**, Silvia Montoto, Stephen Robinson, Irma Khvedelidze, Hervé Finel Ariane Boumendil, Sonja Genadieva-Stavric, Ana Moreno, Gwendolyn Van Gorkom, Marjolein Van Der Poel, Alina Tanase, Harry Schouten, Leyre Bento Peter Dreger, Gonzalo Gutiérrez García, Carmen Martinez, Shimrit Ringelstein Harlev, Norbert Schmitz, Anna Sureda, Natacha Bolaños, Luca Castagna, Sascha Dietrich, Ali Bazarbachi, Christian Gisselbrecht.

### **Update on LWP Activity**

Number of new proposals to EBMT LWP approved each year:

2015	5
2016	6
2017	6
2018	7

Since 2016, 24 studies approved/launched:-

- 14 finished
- 5 ongoing
- 4 protocol pending
- 1 “on hold”

Of 19 launched studies median time from approval to launch 6.5 months (range 1-13 months), median time from approval to final protocol 5 months (2-12 months)

Of 14 finished studies median time from launch to data completed 6.5 months (range 1-15). From data completion to analysis median 1 month (<1-3 months)

### **General Matters**

#### **Annual meeting program**

In Lisbon 2018

- 1 Educational session
- 1 workshop
- 2 meet the expert sessions

In Frankfurt 2019

- 1 Educational session
- 1 workshop
- 2 meet the expert sessions

#### **LWP session Frankfurt 2019**

Keynote Debate: “How should we treat R/R DLBCL in 2019”. Auto (Christian Gisselbrecht), Allo (Steve Robinson), CART (Marie-Jose Kersten)

**Presentation on behalf of the Lymphoma Coalition: Correlation of Patient Information Level with Positive Healthcare Experiences (findings from a Lymphoma Coalition research project) Natacha Bolaños.**

“Better outcome for the Informed Lymphoma Patient”. Global patient survey of patients 6631 patients (14 countries with >100 respondents). Definition of the “Informed patient”. Well informed patients may have lower rates of hospitalisation. Information to patients early in the diagnosis and and treatment is key. Patient organisations can help support patients.

**Educational Issues (AS/SM)**

The EBMT LWP Educational Course 2019 will be held in Bristol. Final dates and venue are yet to be confirmed but will be late September. (18<sup>th</sup>, 19<sup>th</sup> 20<sup>th</sup> September 2019 tentatively)

Bids for the 2020 course are welcome. Two proposals: Munster hosted by Norbert Schmitz and Nantes hosted by Steven Le Guill.

**Manuscript Status (Analysis Completed)**

- 1998-P-01 Lym long F/U (RP/SM); 1st draft written
- 2007-R-01 HL auto late effects update (AS/PD), paper to be circulated to WC/authors; AS committed to send draft by 10/10/18
- 2010-N-02 WM auto; CK, 1st draft written
- 2012-R-04 MALT; AC/SM, accepted BJH
- 2012-R-02E CTCL recent era; RD/ED, 1st draft circulated to WC, then co-authors
- 2013-N-02i PWI prior to SCT; PD, accepted BMT
- 2013-C-01 WM consensus in WM; (CK)- 2nd draft written
- 2014-R-01 alloWM (CK); for JCO?
- 2015-R-03 Rel after auto DLBCL (AS)- 1st draft written
- 2015-R-04 HIV new era (KH); rejected by JCO/Blood/BBMT, submitted to Haematologica
- 2015-R-05 Allo in NHL according to age; CK/PD, accepted BBMT
- 2015-R-01A BV as bridge to SCT in ALCL (AS/ED)
- 2015-R-01A ASCT in ALCL (AS/ED)- ASCT in ALCL-renalysis w/o CR1
- 2015-R-01H BV post allo in HL (AB/AS)- accepted Cancer
- 2015-R-08 Haplo in DLBCL (PD/AS with CIBMTR) rejected by JCO-4 re-analysis and submission to Annals of Oncology
- 2015-R-09 FL Rel post auto in FL (SR)- 2nd draft written
- 2016-R-05 BEAC toxicity (SR); accepted BMT
- 2016-R-01 lbru post allo (PD + CMWP); rejected Blood; to be resubmitted to Leukemia
- 2016-R-04 2nd auto in HL (CM/AS)-pending draft
- 2016-S-01 Checkpoint inhibitors post alloHCT- 20 HL for letter for BMT

- 2016-R-03 Trends in SCT in HL (**SG/AS**)
- 2017-R-01 Trends in SCT in FL (SR) -pending draft
- 2017-R-02 haplo (AB/AS) -pending draft

### **Manuscripts Pending**

- 2007-R-01 HL auto late effects update (AS/PD), paper to be circulated to WC/authors; AS committed to send draft by 10/10/18
- 2014-R-01 alloWM (CK); for JCO?
- 2015-R-01A BV as bridge to SCT in ALCL (AS/ED)
- 2016-R-04 2nd auto in HL (CM/AS)
- 2016-S-01 Checkpoint inhibitors post alloHCT- 20 HL letter for BMT
- 2017-R-01 Trends in SCT in FL (SR)
- 2017-R-02 haplo (AB/AS)

### **Ongoing LWP studies –data collection**

- 2018-R-03 Bing-Neel -3 potential patients
- 2018-R-04 BEAM vs BeEAM

### **Ongoing LWP studies –data analysis**

- 2009-N-02 SCT in blastic plasmacytoid dendritic cell neoplasia (SD with ALWP) 28 LWP (prosp) + 151 ALWP (retrosp) SD presented results-analysis completed- abstract for EBMT including allo and auto-for Blood submission; SD to discuss authorship with ALWP
- 2016-R-02 DLI in lymphoma (SR)- HL sub-study
- 2017-R-05 Ibru post ASCT in MCL (SR)
- 2018-R-02 tandem auto-allo HL (LB/AS)

### **LWP studies to be launched**

- 2018-R-01 Haplo vs cord (Eurocord/CIBMTR)
- 2018-R-05 BV post ASCT in HL (SR)
- 2018-R-06 Allo in DH-DLBCL (NS)
- 2018-R-07 haplo vs MUD/Sib in T-NHL (+ CIBMTR) (PD)

### **Abstracts 2018/19**

#### IWWM 2018

- 2013-C-01 Consensus SCT in WM-poster

#### ISHL-11 2018

- 2016-R-03 Trends in SCT in HL- poster
- 2016-R-04 2nd auto in HL- oral

- 2016-S-01 Check inhibitors pre/post alloHCT- poster with discussion

#### ASH 2018

- 2009-N-02 BPDCN (analysis done)- not submitted- further analysis
- 2016-R-02 DLI in lymphoma- disease specific - submitted
- 2016-R-02 DLI in lymphoma-chimerism submitted
- 2016-R-04 2nd auto in HL submitted
- 2017-R-02 Haplo- submitted
- 2017-R-04 PT-Cy (analysis done)-not submitted- no abstract on time

#### **EBMT 2019**

- 2009-N-02 SCT in BPDCN
- 2017-R-04 PT-Cy2016-R-02 DLI in lymphoma- HL sub-analysis
- 2018-R-04 BEAM vs BeEAM
- 2018-R-02 tandem auto-allo HL

#### **ICML 2019?**

- 2017-R-05 lbru post ASCT MCL

#### **EHA 2019?**

- 2018-R-02 tandem auto-allo HL

#### **New proposals**

The first 3 studies had already been approved at a previous meeting, so the voting was only for prioritising.

- 2018-R-05 BV post auto in HL (presented by SR). 8 in favour of standard priority for the proposal. 0 against.
- 2018-R-06 Allo in DLBCL with double (triple)-hit (presented by NS). 4 in favour of standard priority for the proposal. 0 voted against.. Recommended that initially a survey of centres conducting high numbers of transplants for DLBCL was conducted by NS. Concerns raised regarding the ability to obtain patient tissue from centres wrt the cost, logistics and lack of specific consent.
- 2018-R-07 haplo vs MUD/Sib in T-NHL (presented by PD + CIBMTR). 7 voted in favour of standard priority. 0 voted against.
- Comparison of First Line Chemotherapy vs. Up-front AutoSCT in the Outcome of Patients with Peripheral T-cell Lymphoma (Gonzalo Gutierrez with TCP). 4 in favour of proposal 8 against the proposal. Therefore proposal rejected.

- Long Term Outcome of AlloSCT as First Transplant for Relapsed/Refractory Hodgkin Lymphoma (GG/CM/AS). 8 voted in favour of the proposal 0 against. Proposal accepted for standard priority. Recommendations made to restrict the patient group to a “high risk for failing ASCT” category eg those failing two lines of salvage.

**Next Meeting**

ORF EBMT Annual Meeting Frankfurt 24<sup>th</sup>-27<sup>th</sup> March 2019.